Echo IQ Limited: How Australian AI Is Transforming Heart Disease Detection—and Disrupting Global Healthcare

Echo IQ Limited, trading on the ASX as EIQ, is an Australian med-tech company at the forefront of revolutionizing structural heart disease diagnosis using artificial intelligence. Traditional diagnosis of structural heart disease, especially conditions like aortic stenosis and heart failure, relies on echocardiogram (ultrasound) measurements often subject to human interpretation and error, particularly in resource-limited or rural settings. Even experienced clinicians can overlook subtle patterns in complex data, leading to missed or delayed diagnoses and placing a significant burden on patients, their families, and healthcare systems.Echo IQ’s flagship product, EchoSolv, leverages AI algorithms trained on data from the National Echo Database of Australia (NEDA)—an unmatched repository of over 2 million heart studies linked to 24 years of long-term patient outcomes, including mortality data. The AI analyzes quantitative data from echo reports (not images), identifying hidden correlations among measurements that anticipate severe disease progression. Unlike conventional AI systems that require massive, image-based datasets, EchoSolv’s approach enables faster, more accurate, and more consistent risk detection based on robust, outcome-verified clinical patterns. This makes early intervention possible, helping prevent sudden deterioration or death, particularly in underserved populations where specialist review is scarce.The ethical use of this data is underpinned by rigorous de-identification practices that remove any personally identifiable information before AI training, thereby protecting patient privacy while enabling large-scale medical advancement. The exclusivity of NEDA access (secured by Echo IQ for up to a decade) creates a formidable competitive advantage, as replicating such an outcome-linked dataset would require decades—and extraordinary resources—thus creating a strong data moat.The clinical impact is profound: For notoriously elusive conditions like Heart Failure with Preserved Ejection Fraction (HFpEF), studies show AI-assisted diagnosis can improve detection rates from just 46% to 97%, nearly doubling the number of patients receiving timely, life-altering care. For hospitals, earlier diagnoses mean fewer emergencies and readmissions, resulting in significant cost savings and improved patient outcomes. The business model focuses on software-as-a-service subscriptions for hospitals, and Echo IQ is integrating with existing clinical software to speed adoption.Echo IQ achieved a key milestone in October 2024 with FDA 510(k) clearance for its Aortic Stenosis application (EchoSolv-AS), validating their technology’s safety and effectiveness for U.S. clinical use. The next frontier is heart failure detection—a market estimated at $70 billion globally—aided by research partnerships like the one with Mayo Clinic, with regulatory submissions targeted for late 2025.However, broader adoption hinges on obtaining CPT billing codes from the American Medical Association, critical for hospital reimbursement. Recent market volatility over rumors of rejected reimbursement codes illustrates the industry’s sensitivity to regulatory milestones and the significant financial implications of such policy decisions.Ultimately, Echo IQ’s AI-driven approach advances healthcare from reactive to proactive, making specialist-grade insights available anywhere an echocardiogram can be performed. This positions the company at the intersection of medical innovation, public health policy, and economic sustainability. Its impact is set to grow as it expands its AI applications—potentially setting a new standard for medical diagnostics and reshaping the role of clinicians and algorithms in 21st-century medicine.